Code Biotherapeutics

Code Bio is an emerging next-generation gene therapy company pioneering the development of targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. Leveraging our novel proprietary multivalent synthetic DNA delivery platform, 3DNA, we can overcome many of the challenges inherent with viral based gene therapies, such as immunogenicity, size and delivery limitations, re-dosability, and manufacturing complexity. We are advancing an internal pipeline focused on select rare disease programs and establishing partnerships to take forward programs in both rare and prevalent diseases.